Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.
Giacomo Ruotolo, Charles Harris, Yanzhu Lin et al.
✦ AI-curated · Sources linked
In 30 seconds
This post hoc analysis of two randomised, double-blind, placebo-controlled phase 2 trials assessed lipoprotein and inflammatory biomarkers in adults with overweight or obesity, with or without type 2 diabetes, treated with retatrutide. Across both studies, retatrutide was associated with reductions in several atherogenic lipid measures, including apolipoprotein B (-21.4%, -24.2%) and non-HDL cholesterol (up to -21.0% and -26.9% in Studies 1 and 2, respectively). Inflammatory markers also fell in the obesity-without-diabetes study, but not in the study including participants with diabetes.
Key findings
- Non-HDL cholesterol fell by up to -21.0% in Study 1 and -26.9% in Study 2.
- Apolipoprotein B decreased by -21.4% and -24.2% in Studies 1 and 2, respectively.
- Large triglyceride-rich lipoprotein particles decreased by -84.4% in Study 1 and -76.6% in Study 2.
- In Study 2, high-sensitivity C-reactive protein decreased by -54.8% and interleukin-6 by -29.6%; these reductions were not significant in Study 1.
Why it matters
Atherogenic lipoproteins and inflammatory biomarkers are linked to cardiovascular disease risk. These findings broaden the evidence on retatrutide’s effects beyond weight and glycaemic outcomes, showing changes across several risk-related biomarkers in phase 2 trials. However, biomarker changes do not establish that cardiovascular events are reduced.
What to keep in mind
The biomarker analyses were post hoc and assessed surrogate measures rather than cardiovascular events.